HUTCHMED (NASDAQ:HCM) Raised to “Buy” at StockNews.com

StockNews.com upgraded shares of HUTCHMED (NASDAQ:HCM) from a hold rating to a buy rating in a research report report published on Friday morning.

HUTCHMED Trading Down 7.1 %

NASDAQ HCM opened at $14.99 on Friday. HUTCHMED has a 12 month low of $12.84 and a 12 month high of $21.92. The company has a current ratio of 2.81, a quick ratio of 2.68 and a debt-to-equity ratio of 0.07. The business’s 50-day moving average price is $14.69 and its two-hundred day moving average price is $16.49.

Institutional Trading of HUTCHMED

Several institutional investors and hedge funds have recently modified their holdings of HCM. State Street Corp grew its holdings in HUTCHMED by 0.9% during the third quarter. State Street Corp now owns 349,524 shares of the company’s stock valued at $6,826,000 after purchasing an additional 3,078 shares during the period. Renaissance Technologies LLC increased its holdings in shares of HUTCHMED by 18.4% in the fourth quarter. Renaissance Technologies LLC now owns 188,539 shares of the company’s stock worth $2,717,000 after buying an additional 29,239 shares during the period. Jane Street Group LLC increased its holdings in shares of HUTCHMED by 54.7% in the fourth quarter. Jane Street Group LLC now owns 97,470 shares of the company’s stock worth $1,405,000 after buying an additional 34,473 shares during the period. Connor Clark & Lunn Investment Management Ltd. grew its stake in shares of HUTCHMED by 99.0% in the third quarter. Connor Clark & Lunn Investment Management Ltd. now owns 48,724 shares of the company’s stock worth $952,000 after purchasing an additional 24,245 shares during the last quarter. Finally, XY Capital Ltd bought a new stake in HUTCHMED during the 4th quarter valued at approximately $673,000. 8.82% of the stock is owned by hedge funds and other institutional investors.

HUTCHMED Company Profile

HUTCHMED (China) Ltd. is a holding company, which engages in the research and development, manufacture, and sale of pharmaceuticals and health-oriented consumer products. It operates through the Oncology/Immunology and Other Ventures segments. The Oncology/Immunology segment includes the discovery, development, and commercialization of targeted therapies and immunotherapies for the treatment of cancer and immunological diseases.